Paul Tudor Jones’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$28.8M Sell
24,000
-5,300
-18% -$5.42M 0.04% 349
2026
Q1
$26.9M Sell
29,300
-53,000
-64% -$53.7M 0.05% 314
2025
Q4
$88.4M Buy
82,300
+5,400
+7% +$5.16M 0.16% 81
2025
Q3
$58.7M Buy
76,900
+70,400
+1,083% +$52.4M 0.1% 149
2025
Q2
$5.07M Buy
6,500
+2,500
+63% +$1.94M 0.01% 1080
2025
Q1
$3.3M Sell
4,000
-5,200
-57% -$4.33M 0.01% 1016
2024
Q4
$7.1M Sell
9,200
-8,100
-47% -$6.71M 0.03% 512
2024
Q3
$15.3M Buy
17,300
+700
+4% +$629K 0.06% 252
2024
Q2
$15M Sell
16,600
-18,200
-52% -$14.6M 0.08% 242
2024
Q1
$27.1M Buy
34,800
+23,100
+197% +$16.4M 0.17% 91
2023
Q4
$6.82M Sell
11,700
-9,600
-45% -$5.6M 0.05% 490
2023
Q3
$11.4M Buy
21,300
+19,700
+1,231% +$10.2M 0.11% 186
2023
Q2
$750K Sell
1,600
-1,000
-38% -$419K 0.01% 1481
2023
Q1
$893K Buy
+2,600
New +$877K 0.01% 1269
2022
Q4
Sell
-900
Closed -$291K 2651
2022
Q3
$291K Buy
+900
New +$285K 0.01% 1812

Other funds holding LLY

Paul Tudor Jones's LLY Position: Q2 2026 in Review

Paul Tudor Jones reduced its Eli Lilly (LLY) stake by 75% in Q2 2026, selling an estimated $95.8M and leaving 30,885 shares worth $37M. The position accounts for 0.05% of the portfolio, ranked #275.

Paul Tudor Jones first reported a position in LLY in Q2 2013 and has held it in 40 quarters since. The position peaked at $115M in Q1 2026. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Paul Tudor Jones held 30,885 shares of Eli Lilly worth $37M as of Q2 2026.
  • Paul Tudor Jones sold 93,787 Eli Lilly shares in Q2 2026, an estimated $95.8M.
  • Eli Lilly made up 0.05% of Paul Tudor Jones's portfolio in Q2 2026, its #275 holding.
  • Paul Tudor Jones first reported a position in Eli Lilly in Q2 2013 and has held it in 40 quarters since.
  • Paul Tudor Jones's Eli Lilly position peaked at $115M in Q1 2026.
  • 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.